Semax

Semax — ACTH(4-7) Nootropic Heptapeptide by Dragon Pharma

Semax is Dragon Pharma's formulation of the synthetic nootropic heptapeptide at 5mg per vial — an analogue of the ACTH(4-7) fragment developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a pharmaceutical drug in Russia for cognitive impairment, stroke recovery and neurodegenerative conditions. Unlike the full ACTH molecule which stimulates cortisol production, Semax retains only the CNS-active fragment and produces no adrenocortical effects while delivering significant neurotrophin upregulation, cognitive enhancement and neuroprotection.

Also searched as: Semax 5mg, Semax nootropic peptide, ACTH fragment cognitive, Semax Dragon Pharma.

What Semax Is — The ACTH Fragment Structure

Semax's origin from ACTH and why it doesn't cause cortisol elevation is a critical information gap:

• ACTH (Adrenocorticotropic Hormone) is the pituitary hormone that stimulates the adrenal cortex to produce cortisol. The full 39-amino acid ACTH molecule has both adrenocortical effects (cortisol stimulation via the adrenal glands) and direct CNS effects (cognitive and behavioural modulation)
• The CNS-active fragment of ACTH is the 4-7 sequence (Met-Glu-His-Phe) — this tetrapeptide possesses the cognitive-enhancing properties of ACTH without the cortisol-stimulating effect. It has no binding affinity for the melanocortin receptor 2 (MC2R) which mediates ACTH's adrenocortical action
• Semax extends this fragment with a Pro-Gly-Pro C-terminal addition — the full sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The Pro-Gly-Pro extension dramatically stabilises the peptide against proteolytic degradation, extending its biological half-life and allowing meaningful CNS bioavailability via intranasal administration
• The result: a peptide derived from ACTH that captures its cognitive effects without stimulating the HPA axis — no cortisol elevation, no adrenal stimulation

The Neurotrophin Mechanism — BDNF, NGF and NT-3

Semax's most important mechanism — and the one most consistently missing from competitor content:

• Semax significantly upregulates multiple neurotrophins simultaneously — primarily BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor) and NT-3 (neurotrophin-3)
• BDNF supports survival of existing neurons, encourages growth of new neurons and synapses, and mediates long-term potentiation (LTP) — the synaptic strengthening mechanism underlying learning and memory formation
• NGF is essential for the survival and maintenance of cholinergic neurons in the basal forebrain — the neurons most heavily implicated in attention, memory and cognitive decline in conditions like Alzheimer's disease
• NT-3 supports neuronal survival and synaptic plasticity in a complementary pathway to BDNF
• The simultaneous upregulation of three neurotrophins from a single compound is unusual and represents a broader neuroprotective profile than most individual nootropic interventions — explaining Semax's registration for stroke recovery and neurodegenerative conditions in Russia, not just cognitive enhancement

Acute vs Delayed Effects — Two Timeframes of Action

Semax produces effects across two distinct timeframes that most competitor content treats as a single mechanism:

• Acute effects (minutes to hours): Semax's direct interaction with dopaminergic and serotonergic systems produces rapid improvements in alertness, attention, stress resilience and processing speed. These effects are noticeable within 20-40 minutes of administration and last 4-8 hours — similar in character to cognitive stimulants but without the sympathomimetic side effects of amphetamine-class compounds
• Delayed/cumulative effects (days to weeks): The neurotrophin upregulation effect — particularly BDNF and NGF elevation — is not immediately apparent but accumulates with continued use. Sustained neurotrophin elevation promotes synaptic remodelling, new neural connection formation and neuroprotective adaptations. These effects persist beyond active dosing and represent the neuroprotective dimension of Semax that distinguishes it from conventional cognitive stimulants

Semax vs Selank — The Paired Russian Peptide Comparison

Semax in an AAS and Performance Context

Beyond general cognitive enhancement, Semax has specific relevance in performance and AAS contexts:

• AAS cycles — particularly those using aggressive cutting, caloric deficits, or high Trenbolone doses — frequently impair cognitive function through CNS stress, hormonal fluctuation and sleep disruption. Semax's acute cognitive enhancement provides performance-maintaining mental clarity during these phases
• The BDNF and NGF elevation from repeated Semax use provides neuroprotective benefits that may counteract the neurological stress associated with prolonged high-dose AAS protocols
• Pre-competition cognitive demand — mental clarity for posing, peak week management, competitive mindset — is an area where Semax's stimulating nootropic profile is directly applicable

Effects and Benefits

• Acute cognitive enhancement — improved attention, processing speed, working memory and stress resilience within minutes of administration
• BDNF, NGF and NT-3 upregulation — sustained neurotrophin elevation with cumulative neuroprotective effects
• No cortisol or HPA axis stimulation — ACTH(4-7) fragment has no adrenocortical binding activity
• No physical dependence — not classified as addictive; no withdrawal syndrome documented
• Registered pharmaceutical use in Russia for stroke recovery and cognitive impairment — clinical evidence base beyond animal studies
• No testosterone suppression — no PCT required

Dosage and Administration

At 5mg per vial and 400mcg per dose, one vial provides approximately 12 doses. Intranasal administration is particularly efficient for Semax — the Pro-Gly-Pro extension was specifically designed to survive nasal mucosal enzymatic degradation, and the olfactory pathway provides rapid CNS delivery. Reconstitute with bacteriostatic water and store refrigerated at 2-8°C after reconstitution. Intranasal administration uses a nasal atomiser with 1-2 drops per nostril at the chosen dose volume.